Sanofi (France)
NEWS
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.
Almost 15,000 physicians, scientists, health care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association’s 79th Scientific Sessions in San Francisco this week.
A Phase III trial compared Sanofi’s Soliqua/Suliqua to other GLP-1 receptor agonists (GLP-1 RA), with Soliqua showing a superior decrease of average blood sugar level (HbA1c) after 26 weeks.
Brandicourt, who has helmed Sanofi since 2015, will retire from his CEO role this fall. Sanofi has a rule that its CEO cannot be over the age of 65.
Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi and six major health systems.
Boston and its surrounding communities, particularly the community of Cambridge, have become the hottest biotech hotspot on the East Coast of the United States.
Dengvaxia is approved for dengue disease caused by serotypes 1-4 in people 9 through 16 years of age who are living in areas of the U.S. who have had a laboratory-documented previous infection.
Pharma, biotech and life science companies from across the globe share data and progress on pipelines and other company events.
This week has a number of approvals expected by the U.S. Food and Drug Administration. Let’s take a look.
JOBS
IN THE PRESS